

Estimate changes			
TP change			
Rating change			
Bloomberg	GCPL IN		
Equity Shares (m)	1023		
M.Cap.(INRb)/(USDb)	1248.2 / 14.2		
52-Week Range (INR)	1542 / 980		
1, 6, 12 Rel. Per (%)	0/6/-20		
12M Avg Val (INR M)	1710		
Financials & Valuations (INR b)			
Y/E March	2026E	2027E	2028E
Sales	163.4	180.2	198.9
Sales Gr. (%)	13.7	10.3	10.3
EBITDA	32.4	38.3	43.5
EBITDA mrg. (%)	19.8	21.2	21.9
Adj. PAT	22.5	27.5	31.9
Adj. EPS (INR)	22.0	26.8	31.2
EPS Gr. (%)	18.9	21.9	16.3
BV/Sh.(INR)	123.2	128.5	136.2
Ratios			
RoE (%)	18.3	21.3	23.6
RoCE (%)	16.1	19.6	22.3
Payout (%)	99.9	89.4	83.3
Valuations			
P/E (x)	55.5	45.5	39.2
P/BV (x)	9.9	9.5	9.0
EV/EBITDA (x)	39.2	32.9	28.7
Div. Yield (%)	1.8	2.0	2.1

Shareholding Pattern (%)			
As On	Jun-25	Mar-25	Jun-24
Promoter	53.1	53.1	63.0
DII	12.4	12.2	9.3
FII	19.4	19.5	22.4
Others	15.2	15.2	5.3

FII includes depository receipts

CMP: INR1,220 TP: INR1,400 (+15%)

Buy

Healthy volume delivery; margin recovery likely in 2HFY26

- Godrej Consumer's (GCPL) consolidated revenue rose 10% YoY to INR36.6b (est. INR36.8b), while volume growth stood at 8%. EBITDA declined 4% YoY (est. +4%) due to weak India and Indonesia margins.
- India's revenue rose 8%, while volume grew 5%. Ex-soaps, volume growth was in mid-teens. Home Care delivered 16% revenue growth. HI delivered high single-digit volumes, led by double-digit growth in electrics. Air Fresheners and Fabric Care delivered strong double-digit volume growth.
- The Personal Care portfolio posted 1% YoY revenue growth. Personal Wash witnessed a price-volume rebalancing due to commodity volatility, resulting in flattish revenue. Hair Color volume grew in strong double digits. Deodorants and Sexual Wellness grew in mid-teens.
- International revenue rose 15% despite Indonesia clocking a 4% decline. GUAM and LATAM reported strong ~30% growth. In Indonesia, macro headwinds and increased competitive pricing intensity led to a flat UVG.
- India's EBITDA declined 6% YoY, impacted by sustained GM pressure (500bp down), which was fueled by strategic price reductions in aerosols and hair color. Meanwhile, soap margins remained under pressure due to elevated inventory costs. International EBIT remained flat YoY, weighed down by intensified pricing competition in Indonesia (9% EBIT down).
- The Indian business is gradually getting back on track for accelerated volume growth, with 1Q performance reinforcing confidence in an improving trajectory. With palm oil prices easing towards end-June, the company is well-positioned for margin recovery in 2HFY26, supporting overall profitability. This combination of volume traction and margin tailwinds strengthens earnings visibility. We model 11%/13% revenue and EBITDA CAGR for FY25-28E.
- The company is on track to expand its TAM and strengthen its core portfolio. Under project Vistaara 2.0, the company plans to double its outlet coverage and triple its village coverage. Given the growth-centric focus, we remain constructive on GCPL and reiterate our **BUY** rating with a TP of **INR1,400 (based on 50x Jun'27E EPS)**.

India's (ex-Soap) UVG in mid-teens; miss on margin

Consolidated performance

- Healthy volume growth:** Consol. net sales grew 10% YoY to INR36.6b (est. INR36.8b). Consolidated volume growth was 8%.
- Pressure on margins:** Gross margins contracted 400bp YoY to 51.9% (est. 52.5%). Employee expenses rose 11%, other expenses rose 11%, while ad spends declined 5%. EBITDA margin contracted 280bp YoY to 19% (est. 20.5%). The company remains on track to achieve ~200bp savings in media investments, without any compromise on reach or brand visibility.

Naveen Trivedi – Research Analyst (Naveen.Trivedi@motilaloswal.com)

Research Analyst: Amey Tiwari (Amey.Tiwari@MotilalOswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

- **Miss on profitability:** EBITDA declined 4% YoY to INR6.9b (est. INR7.5b). PBT was at INR6.3b (est. INR6.8b), down 4% YoY. APAT was flat YoY at INR4.7b (est. 5.1b).
- **International performance:** Indonesia's revenue declined 4% both in INR and CC terms. Volume growth was flat, impacted by macro headwinds and intensified price competition. In Indonesia, Hair Colours continued its strong performance and delivered double-digit growth, led by Shampoo Hair Colour. Baby Care continued to grow and gain market share. The Indonesian business's EBITDA declined 13% due to competitive pricing. GAUM's revenue grew 30%, while EBITDA rose 15%. In GAUM, new products in Hair Fashion are performing well across key markets, while the Aer Pocket launch in Nigeria, South Africa, Mozambique, and Zambia has seen strong traction and repeat sales. The Hair Care range continues to deliver robust double-digit growth across Africa.
- **Standalone performance:** Net sales (including OOI) grew 8% YoY to INR23.1b in 1QFY26. The Indian business reported underlying volume growth of 5% YoY (in line). Ex- Soaps, India's UVG growth was in mid-teens. The Home Care business registered robust 16% revenue growth, while Personal Care posted 1% growth. Gross margin contracted 510bp YoY to 51.3%. GP declined 2%, with EBITDA margin contracting 320bp YoY to 21.6% (est. 22.9%). EBITDA declined 6% YoY to INR5.9b.

Highlights from the management commentary

- Consumption trends are improving modestly, with this quarter being slightly better than the previous one. Growth was relatively easier than in earlier quarters, especially outside of soaps.
- GCPL expects normative margins to return in 2HFY26 through: 1) Cost-saving initiatives: ANP efficiency, media negotiations, supply chain improvements from new factories and 2) No major structural margin correction anticipated in Indonesia.
- In India, management has guided for high single-digit UVG, high single-digit revenue growth in INR terms, and double-digit EBITDA growth for FY26.
- Indonesia: Margins are expected to recover from 3Q, assuming no further competitive disruptions.

Valuation and view

- We cut our EPS estimates by 5% each for FY26 on account of a miss on margin, while we maintain estimates for FY27.
- GCPL faced demand headwinds in its Indian business during the quarter due to grammage reduction in soaps, which impacted margins. However, palm oil prices began to moderate towards the end of June. The benefits of this decline are expected to flow through only in 2HFY26. The company's disruptive innovations, introduction of access packs, and expansion into new growth categories are likely to contribute to the growth trajectory. Additionally, savings in media spends of 200bp will also help restore margins.
- Besides, there has been a consistent effort to fix gaps in profitability/growth for its international business. **We reiterate our BUY rating with a TP of INR1,400 (based on 50x Jun'27E EPS).**

Y/E March	Quarterly Performance (Consolidated)								(INR m)			
	FY25				FY26E				FY25	FY26E	FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE				
Domestic volume Growth (%)	8	7	0	4	5	7	6	8	5	7	5	
Net Sales (including OOI)	33,316	36,663	37,684	35,980	36,619	41,999	42,941	41,153	1,43,643	1,63,372	36,759	-0.4
YoY change (%)	-3.4	1.8	3.0	6.3	9.9	14.6	14.0	14.4	1.9	13.7	10.3	
Gross Profit	18,608	20,381	20,402	18,890	19,005	21,975	23,241	22,617	78,282	86,838	19,301	-1.5
Margin (%)	55.9	55.6	54.1	52.5	51.9	52.3	54.1	55.0	54.5	53.2	52.5	
Other Operating Exp.	11,346	12,764	12,843	11,298	12,060	13,909	14,476	14,076	48,251	54,476	11,763	
EBITDA	7,262	7,617	7,559	7,592	6,946	8,066	8,765	8,541	30,031	32,362	7,538	-7.9
Margins (%)	21.8	20.8	20.1	21.1	19.0	19.2	20.4	20.8	20.9	19.8	20.5	
YoY growth (%)	6.5	5.3	-16.4	-0.2	-4.4	5.9	15.9	12.5	-2.2	7.8	3.8	
Depreciation	495	501	619	726	594	625	650	655	2,340	2,524	700	
Interest	878	831	897	896	865	835	835	849	3,501	3,384	850	
Other Income	751	843	831	737	845	900	900	928	3,161	3,573	817	
PBT	6,623	7,107	6,874	6,708	6,332	7,506	8,180	7,965	27,312	30,027	6,805	-6.9
Tax	1,933	2,154	1,834	2,275	1,613	1,876	2,045	1,973	8,196	7,507	1,701	
Rate (%)	29.2	30.3	26.7	33.9	25.5	25.0	25.0	24.8	30.0	25.0	25.0	
Adj PAT	4,649	4,953	5,025	4,321	4,669	5,629	6,135	5,992	18,948	22,520	5,104	-8.5
YoY change (%)	23.6	12.2	-14.3	-24.8	0.4	13.6	22.1	38.7	-4.2	18.9	9.8	
Reported PAT	4,507	4,913	4,983	4,119	4,525	5,629	6,135	5,992	18,522	22,520	5,104	-11.3

E: MOFSL Estimate

India business segment highlights

Home Care business registered 16% revenue growth.

- **Household Insecticides** delivered a solid performance with strong high single-digit UVG. Electrics posted double-digit growth, while incense sticks grew ~2.5x. The non-mosquito portfolio saw strong double-digit UVG, aided by the launch of Mini ARG. The company gained market share across all key segments.
- **Air Fresheners** continued to post strong double-digit growth across formats. Aer-O scaled up ~2x and Aer Spray delivered robust growth, driven by a shift in value from trade to consumer. The newly launched Aer Plug further strengthened the portfolio, with the company retaining its market leadership.
- **Fabric Care** reported strong double-digit UVG for the sixth straight quarter, supported by continued market share gains led by Godrej Fab.

The Personal Care business recorded revenue growth of 1%.

- **Personal Wash** witnessed a price-volume rebalancing due to commodity volatility, resulting in flattish revenue performance. Competitive pricing, reduced trade margins, and grammage cuts impacted growth, though market share remains positive. Margin pressure is expected to persist in 2QFY26, with a likely return to normalized margins in 2HFY26, driven by softening palm oil prices.
- **Hair Colour** delivered strong double-digit growth in UVG, led by robust performance from Godrej Expert Rich Crème and Godrej Selfie Shampoo Hair Colour. Market share remains positive across both crème and shampoo formats.
- The **Deodorants** portfolio grew in mid-teens. The newly launched *Amazon Woods 4X* has seen healthy repeat purchases, while *Bloq Anti-Perspirant*, launched in Tamil Nadu, is gaining traction with strong repeat usage.

Exhibit 1: Snapshot of 1QFY26 performance as reported by the company

Growth (%)

	Consolidated	Standalone
UVG	8	5
Net sales	10	8
Net sales (constant currency)	11	-
EBITDA	-3	-6
Net profit (reported)	0	-4
Net profit (without exceptional and one-off items)	0	-4

Source: Company, MOFSL

Exhibit 2: Snapshot of sales by geography

International business	1QFY26		
	Sales (INR m)	Growth (%)	CC growth (%)
India – Reported	23,070	8	-
Indonesia	4,480	-4	-4
Africa, USA & Middle East (organic)	7,060	30	29
Latin America and SAARC	2,240	18	29
Total net sales (Reported)	36,420	10	11

Source: Company, MOFSL

Highlights from the conference call

Business operations and environment

- Consumption trends are improving modestly, with this quarter being slightly better than the previous one.
- Growth was slightly easier than in earlier quarters, especially outside of soaps.
- The quarter had mixed weather: unusually hot April, poor May in North India, followed by recovery in June.
- Rural demand showed signs of gradual recovery.
- GCPL is optimistic about domestic macro, but cautious due to geopolitical uncertainties and palm oil volatility.
- Pet Care (Ninja brand) launched in Tamil Nadu; initial consumer acceptance is strong, but it is a long gestation category.

Cost and margins

- India's standalone EBITDA declined 6% due to: 1) Margin impact from price cuts in aerosols and hair color and 2) Soaps margin remaining in the low range due to high inventory costs and grammage reduction.
- Ex-Soaps, the portfolio saw mid-teen UVG, but margins slightly contracted due to strategic pricing actions.
- GCPL expects normative margins to return in 2HFY26 through: 1) Cost-saving initiatives: ANP efficiency, media negotiations, supply chain improvements from new factories, and 2) No major structural margin correction anticipated in Indonesia.

Home care

Household Insecticides (HI)

- The HI business's volumes grew in high single digits, led by double-digit growth in electrics.



- GCPL gained unprecedented market share in electrics and, for the first time in a decade, gained share in overall HI.
- New molecule (R&F) has been successful; exclusivity gives competitive moat; strong consumer repeat and recall.
- The incense stick category continues to grow, restricting premium category expansion.
- Future HI volume growth expected to be in high single digits, barring seasonality changes.
- No clear boost from early monsoons; April was too hot and seasonality was average overall.

Air Fresheners

- Air Pocket launched in Africa and other markets have received strong consumer traction.
- GCPL is investing heavily in this category across markets such as Africa and India.

Personal care

Soaps

- Soaps performed poorly due to sharp grammage cuts (e.g., 55g → 43g in INR10 pack) and a weak season in May.
- Market share gain continues but at a slower pace than usual.
- Price increase implemented earlier will mark its anniversary in 2Q and should help improve reported numbers.
- Long-term volume growth is expected to return to 2-3% p.a., in line with population growth.

Hair Color

- The price drop in large hair color packs (INR42 → INR37) is expected to correct the value gap with INR15 pack, which has performed well.
- Margin impact from price correction is expected to be recovered via cost savings.

Deodorants & Antiperspirants

- Amazon Woods 4X launched successfully; consumer traction is strong.
- Block antiperspirant (INR99) aims to build a new habit; slow category build-up expected.
- Strategic shift from trade-led to consumer-led pricing — pilot in Tamil Nadu (MRP cut from INR230 to INR99, with same margin %) resulted in explosive growth.
- GCPL plans to scale this INR99 price-point strategy gradually across markets.

Laundry Liquids

- FAB detergent continues to gain share and consumer acceptance despite competition (e.g., Unilever's Sunlight at INR70/ltr).
- Price hike of 5% was taken on FAB with no negative impact on volumes.
- GCPL sees FAB as a branded upgrade play from powders, not a pricing war.

Park Avenue and Kamasutra

- Park Avenue and KS are central to GCPL's personal care strategy, especially in deodorants and the new antiperspirant segment.
- GCPL is transforming the category from high-trade-margin-driven to consumer-led through a price architecture reset.
- The INR99 pricing innovation is delivering strong results, especially in pilot regions.
- Block antiperspirant is a long-term strategic bet, aimed at category creation and consumer habit change.
- Distribution strength offers GCPL an edge in driving retail-led adoption of these changes.

International business

Indonesia

- The business was impacted by a macro slowdown and heightened price competition, especially in HI and air fresheners.
- GCPL initially delayed its reaction to pricing aggression but matched prices later in 1Q.
- Price gap was 7-8% higher than competition; now corrected.
- Margin pressures are expected to be temporary, with normalization likely by 3QFY26.

Africa

- Sales grew 30%, EBITDA grew 15%.
- Margin dilution seen due to heavy investments in Air Pocket and on-ground marketing.
- About 10-12% of growth is attributed to base correction from last year's inventory clean-up.
- Double-digit growth is expected to continue, assuming macro remains supportive.

Latin America

- The market continued to post high single-digit volume growth.
- EBITDA margins are now in double digits.

FY26 guidance

- In India, management guided high single-digit UVG, revenue growth of high single-digit in INR terms, and double-digit EBITDA growth for FY26.
- Margin recovery is expected in 2HFY26 as palm oil benefits flow in.
- HI: Maintain high single-digit volume growth guidance.
- **Soaps:** Expect improvement from 2QFY26 as pricing and season normalize.
- **Africa:** Sustainable double-digit growth expected.
- **Indonesia:** Margins to recover from 3Q assuming no further competitive disruptions.

Key exhibits

Segment revenue (INR m)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26
India	20,055	21,682	22,041	20,336	21,629	23,007	22,617	21,849	23,300
Indonesia	4,507	4,730	4,665	4,983	4,651	5,138	5,079	5,043	4,481
Africa (including SON)	8,486	8,158	9,233	5,937	5,446	6,446	7,724	6,903	7,074
Others	1,808	1,826	993	2,900	1,953	2,476	2,636	2,572	2,264
Less: Inter-segment eliminations	-366.2	-376.2	-335.7	-300.4	-363.9	-402.7	-371	-388.3	-500.3
Net Sales from operations	34,489	36,020	36,596	33,856	33,316	36,663	37,684	35,980	36,619
Segment revenue growth (%)									
India	8.4	9.2	9.7	11.6	7.9	6.1	2.6	7.4	7.7
Indonesia	19.7	15.7	7.7	14.7	3.2	8.6	8.9	1.2	-3.7
Africa (including SON)	8.9	-5.0	-8.3	-22.9	-35.8	-21.0	-16.3	16.3	29.9
Others	17.4	4.7	-45.7	42.5	8.0	35.6	165.4	-11.3	15.9
Less: Inter-segment eliminations	8.1	8.0	-1.3	-3.0	-0.6	7.0	10.5	29.3	37.5
Net Sales from operations	10.4	6.2	1.7	5.8	-3.4	1.8	3.0	6.3	9.9
Segment EBIT (INR m)									
India	6,336	6,826	6,762	5,797	5,705	6,068	5,382	5,040	5,321
Indonesia	995	1,013	1,166	1,332	1,172	1,092	1,187	1,472	1,063
Africa (including SON)	440.1	499.4	825	665.1	625.4	769.4	1014.4	998.5	732.9
Others	79.4	34.9	24.7	74.2	146.2	146.3	300.3	210.2	202
Less: Inter-segment eliminations	-1493.5	-1281	-208.7	-171.1	-128	-120.2	-111.9	-117.2	-121.9
Net EBIT from operations	6,357	7,092	8,569	7,697	7,521	7,955	7,772	7,603	7,197
Segment EBIT growth (%)									
India	54.5	57.3	20.7	16.8	-10.0	-11.1	-20.4	-13.0	-6.7
Indonesia	72.7	37.5	23.1	27.2	17.9	7.7	1.8	10.5	-9.3
Africa (including SON)	79.0	143.8	32.9	123.9	42.1	54.1	23.0	50.1	17.2
Others	217.6	-56.5	-80.9	-60.0	84.1	319.2	1115.8	183.3	38.2
Net EBIT from operations	29.4	34.2	20.3	22.1	18.3	12.2	-9.3	-1.2	-4.3
Segment EBIT mix (%)									
India	100	96	79	75	76	76	69	66	74
Indonesia	16	14	14	17	16	14	15	19	15
Africa (including SON)	7	7	10	9	8	10	13	13	10
Others	1	0	0	1	2	2	4	3	3
Less: Inter-segment eliminations	-23	-18	-2	-2	-2	-2	-1	-2	-2
Net EBIT from operations	100								
Segment EBIT margin (%)									
India	31.6	31.5	30.7	28.5	26.4	26.4	23.8	23.1	22.8
Indonesia	22.1	21.4	25.0	26.7	25.2	21.2	23.4	29.2	23.7
Africa (including SON)	5.2	6.1	8.9	11.2	11.5	11.9	13.1	14.5	10.4
Others	4.4	1.9	2.5	2.6	7.5	5.9	11.4	8.2	8.9
Net EBIT margin from operations	18.4	19.7	23.4	22.7	22.6	21.7	20.6	21.1	19.7
Segment EBIT margin change (%)									
India	9.4	9.6	2.8	1.3	-5.2	-5.1	-6.9	-5.4	-3.5
Indonesia	6.8	3.4	3.1	2.6	3.1	-0.2	-1.6	2.5	-1.5
Africa (including SON)	2.0	3.7	2.8	7.3	6.3	5.8	4.2	3.3	-1.1
Others	2.8	-2.7	-4.6	-6.6	3.1	4.0	8.9	5.6	1.4
Overall EBIT change	2.7	4.1	3.6	3.0	4.1	2.0	-2.8	-1.6	-2.9

Valuation and view

- We cut our EPS estimates by 5% each for FY26 on account of a miss on margin, while we maintain estimates for FY27.
- GCPL faced demand headwinds in its India business during the quarter due to grammage reduction in soaps, which impacted margins. However, palm oil prices began to moderate towards the end of June. The benefits of this decline are expected to flow through only in 2HFY26. The company's disruptive innovations, introduction of access packs, and expansion into new growth categories are expected to contribute to the growth trajectory. Additionally, savings in media spends of 200bp will also help restore margins.
- Besides, there has been a consistent effort to fix gaps in profitability/growth for its international business. **We reiterate our BUY rating with a TP of INR1,400 (based on 50x Jun'27E EPS).**

Exhibit 3: We cut our EPS estimates by 5% for FY26; maintain for FY27

(INR b)	Old		New		Change	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Sales	159.3	175.6	163.4	180.2	2.6	2.6
EBITDA	34.2	38.8	32.4	38.3	-5.3	-1.4
PAT	23.7	27.7	22.5	27.5	-5.1	-0.9

Source: Company, MOFSL

Exhibit 4: P/E ratio (x) for GCPL





Exhibit 5: P/E ratio (x) for the Consumer sector



Financials and valuations

Income Statement										(INR m)
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E	
Net Sales	99,108	1,10,286	1,22,765	1,33,160	1,40,961	1,43,643	1,63,372	1,80,246	1,98,877	
Change (%)	-3.9	11.3	11.3	8.5	5.9	1.9	13.7	10.3	10.3	
Cost of Goods Sold	42,617	49,294	60,751	67,028	63,203	65,361	76,534	83,245	90,658	
Gross Profit	56,491	60,992	62,014	66,132	77,758	78,282	86,838	97,000	1,08,219	
Margin (%)	57.0	55.3	50.5	49.7	55.2	54.5	53.2	53.8	54.4	
Total Expenditure	77,764	86,954	97,848	1,07,768	1,10,258	1,13,612	1,31,010	1,41,980	1,55,344	
EBITDA	21,345	23,332	24,917	25,392	30,704	30,031	32,362	38,266	43,532	
Change (%)	1.5	9.3	6.8	1.9	20.9	-2.2	7.8	18.2	13.8	
Margin (%)	21.5	21.2	20.3	19.1	21.8	20.9	19.8	21.2	21.9	
Depreciation	1,973	2,039	2,099	2,363	2,410	2,340	2,524	2,592	2,706	
Int. and Fin. Charges	2,174	1,266	1,102	1,757	2,964	3,501	3,384	2,743	1,763	
Other Income	1,123	671	897	1,684	2,690	3,161	3,573	3,684	3,505	
PBT	18,321	20,698	22,614	22,955	28,020	27,351	30,027	36,615	42,569	
Change (%)	0.8	13.0	9.3	1.5	22.1	-2.4	9.8	21.9	16.3	
Margin (%)	18.5	18.8	18.4	17.2	19.9	19.0	18.4	20.3	21.4	
Tax	2,638	3,595	3,719	4,303	7,588	8,196	7,507	9,154	10,642	
Deferred Tax										
Total tax	2,638	3,595	3,719	4,303	7,588	8,196	7,507	9,154	10,642	
Tax Rate (%)	14.4	17.4	16.4	18.7	27.1	30.0	25.0	25.0	25.0	
Minority interest	-8	0	-3	-4	0	0	0	0	0	
Adjusted PAT	14,725	17,150	17,936	17,450	19,787	18,948	22,520	27,461	31,927	
Non-rec. (Exp.)/Income	-811	-445	-98	-541	-24,769	-632	0	0	0	
Reported PAT	14,794	16,108	17,834	17,028	-5,605	18,522	22,520	27,461	31,927	

Balance Sheet										(INR m)
Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E	
Share Capital	1,022	1,023	1,023	1,023	1,023	1,023	1,023	1,023	1,023	
Reserves	77,961	93,367	1,11,302	1,36,920	1,25,097	1,19,016	1,24,981	1,30,390	1,38,327	
Networth	78,984	94,389	1,12,325	1,37,942	1,26,120	1,20,039	1,26,004	1,31,413	1,39,350	
Loans	26,637	17,683	16,077	10,340	31,546	38,826	24,826	16,826	8,826	
Deferred Liability	-5,701	-6,378	-6,796	-6,412	-2,804	938	938	938	938	
Capital Employed	99,920	1,05,695	1,21,606	1,41,870	1,54,863	1,59,803	1,51,768	1,49,177	1,49,114	
Gross Block	45,229	46,302	45,888	49,936	62,817	63,709	66,709	69,709	72,709	
Less: Accum. Depn.	6,308	8,553	7,463	8,822	8,785	9,262	11,786	14,378	17,084	
Net Fixed Assets	38,921	37,749	38,425	41,114	54,033	54,447	54,923	55,332	55,626	
Capital WIP	570	574	1,164	454	834	4,636	4,636	4,636	4,636	
Goodwill	53,393	51,299	53,768	58,223	50,264	51,454	51,454	51,454	51,454	
Non Curr Investments	348	194	1,711	8,393	17,875	6,279	6,779	7,279	7,779	
Current Investments	6,372	6,572	8,443	21,897	17,162	31,027	25,527	21,027	16,527	
Currents Assets	43,498	39,672	47,279	37,880	40,767	45,131	46,065	50,676	58,305	
Inventory	17,031	17,163	21,299	15,372	12,709	14,186	22,495	24,818	27,384	
Account Receivables	11,573	10,045	11,163	12,453	15,354	18,191	15,278	16,856	18,598	
Cash and Bank Balance	7,702	6,722	7,843	3,907	5,469	4,831	-322	-204	2,464	
Loans and Advances	259	264	1	1	0	0	0	0	0	
Other Current Assets	6,934	5,479	6,974	6,147	7,235	7,923	8,614	9,205	9,858	
Curr. Liab. & Prov.	43,182	30,366	29,185	26,091	26,071	33,172	37,617	41,228	45,214	
Account Payables	24,805	20,124	21,631	18,232	16,755	21,421	24,618	27,160	29,968	
Other Liabilities	16,648	8,371	5,723	6,073	6,741	9,186	10,287	11,229	12,268	
Provisions	1,729	1,871	1,832	1,786	2,576	2,565	2,713	2,839	2,978	
Net Current Assets	316	9,307	18,094	11,789	14,696	11,959	8,448	9,449	13,091	
Net Assets	99,920	1,05,695	1,21,606	1,41,870	1,54,863	1,59,803	1,51,768	1,49,177	1,49,114	

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
Basic (INR)									
EPS	14.4	16.8	17.5	17.1	19.3	18.5	22.0	26.8	31.2
Cash EPS	16.3	18.8	19.6	19.4	21.7	20.8	24.5	29.4	33.9
BV/Share	77.3	92.3	109.8	134.9	123.3	117.3	123.2	128.5	136.2
DPS	6.0	0.0	0.0	0.0	15.0	20.0	22.0	24.0	26.0
Payout (%)	41.7	0.0	0.0	0.0	77.5	108.0	99.9	89.4	83.3
Valuation (x)									
P/E	84.9	72.9	69.7	71.6	63.2	66.0	55.5	45.5	39.2
Cash P/E	74.8	65.1	62.4	63.1	56.3	58.7	49.9	41.6	36.1
EV/Sales	12.8	11.4	10.2	9.4	8.9	8.9	7.8	7.0	6.3
EV/EBITDA	59.4	54.0	50.4	49.1	41.0	42.6	39.2	32.9	28.7
P/BV	15.8	13.2	11.1	9.1	9.9	10.4	9.9	9.5	9.0
Dividend Yield	0.5	0.0	0.0	0.0	1.2	1.6	1.8	2.0	2.1
Return Ratios (%)									
RoE	19.4	19.8	17.4	13.9	15.0	15.4	18.3	21.3	23.6
RoCE (Post-tax)	17.8	17.7	17.4	15.2	15.2	13.7	16.1	19.6	22.3
RoIC	19.9	19.9	19.6	17.8	18.7	17.1	19.6	23.1	26.2
Working Capital Ratios									
Debtor (Days)	43	33	33	34	40	46	34	34	34
Asset Turnover (x)	2.5	2.9	3.1	3.2	2.6	2.4	2.7	3.0	3.3
Leverage Ratio									
Debt/Equity (x)	0.3	0.2	0.1	0.1	0.3	0.3	0.2	0.1	0.1

Cash Flow Statement

Y/E March	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E
Profit before Tax	18,415	20,804	21,553	21,327	1,982	26,719	30,027	36,615	42,569
Net interest	1,412	916	506	802	1,094	1,153	1,598	901	10
Direct Taxes Paid	-3,441	-3,972	-4,475	-4,185	-3,739	-4,701	-7,507	-9,154	-10,642
(Inc)/Dec in WC	-2,613	-452	-5,362	933	-4,559	351	-1,642	-882	-974
Others	2,109	3,001	2,284	2,629	25,921	2,245	2,524	2,592	2,706
CF from Operations	15,881	20,296	14,506	21,507	20,699	25,767	25,000	30,072	33,668
Inc in FA	-1,520	-1,639	-2,765	-2,197	-2,766	-5,592	-3,000	-3,000	-3,000
Free Cash Flow	14,361	18,658	11,741	19,309	17,933	20,175	22,000	27,072	30,668
Pur of Investments	-1,305	-289	-4,744	-16,377	-6,130	477	5,000	4,000	4,000
Others	-1,348	-1,186	-2,081	1,075	-24,305	524	7,737	4,342	4,360
CF from Investments	-4,173	-3,114	-9,589	-17,499	-33,201	-4,591	9,737	5,342	5,360
Inc in Debt	-1,280	-16,194	-2,198	-6,344	22,652	7,318	-14,000	-8,000	-8,000
Dividend Paid	-9,859	0	0	0	-5,114	-25,573	-22,506	-24,552	-26,598
Interest Paid	-1,519	-1,589	-1,123	-1,116	-2,620	-3,111	-3,384	-2,743	-1,763
CF from Fin. Activity	-12,953	-18,162	-3,795	-7,943	14,064	-21,815	-39,890	-35,295	-36,361
Inc/Dec of Cash	-1,246	-980	1,121	-3,936	1,562	-639	-5,153	119	2,668
Add: Beginning Balance	8,947	7,702	6,722	7,843	3,907	5,469	4,831	-322	-204
Closing Balance	7,702	6,722	7,843	3,907	5,469	4,831	-322	-204	2,464

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report.
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Patel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022- 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrgrievances@motilaloswal.com.